Indaptus Therapeutics, Inc. — fact timeline

Indaptus Therapeutics, Inc. underwent a change of control involving Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng for $11,200,000 (closed 2026-03-23).

“on March 23, 2026, David Lazar sold, in accordance with the rights afforded to Mr. Lazar in the Purchase Agreement, all of his interest and rights in the 700,000 shares of Series AAA Preferred Stock and all of his interest and rights to 196,800 shares of Series AA Preferred Stock to Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng (the “Purchasers”) in certain percentages set forth in the definitive agreements related to such transaction, for an aggregate purchase price of $11,200,000 (the “Purchase Price”).”

Indaptus Therapeutics, Inc.: Amended Section 2.13 of the Bylaws to provide that stockholder action must be at a meeting and not by written consent, unless the Certificate of Incorporation provides otherwise (effective 2026-02-27).

“upon filing of the Certificate of Amendment with the Secretary of State of Delaware, Section 2.13 of the Company’s Amended and Restated Bylaws shall be deemed to be amended as follows: “Unless otherwise provided in the Certificate of Incorporation, any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders of the Corporation and may not be effected by any consent in writing by such stockholders.””

Indaptus Therapeutics, Inc.: Approved amendments to the Charter to increase authorized common stock to 1,000,000,000 shares and permit stockholder action by written consent (effective 2026-02-27).

“stockholders of the Company approved amendments to the Company’s Charter to (i) increase the number of authorized shares of our common stock to 1,000,000,000 (one billion) shares, and (ii) permit stockholder approval by written consent in lieu of a meeting.”

Indaptus Therapeutics, Inc. underwent a change of control involving David E. Lazar (closed 2026-02-26).

“greement (the “Purchase Agreement”) with David E. Lazar (“Mr. Lazar”) pursuant to which he purchased from the Company 300,000 shares of Series AA Convertible Preferred Stock (the “Series AA Preferred Stock”) and 700,000 shares of Series”

Indaptus Therapeutics, Inc. entered into Repricing Agreements with Executing Holders (effective 2026-02-11).

“On February 11, 2026, Indaptus Therapeutics, Inc. (the “Company”) entered into warrant repricing agreements (the “Repricing Agreements”) with certain holders (the “Executing Holders”) of warrants to purchase an aggregate of 913,638 shares of common stock of the Company that were originally issued in financing rounds during 2024 and 2025 at exercise prices ranging from $8.30 to $47.60 (the “Executing Warrants”).”

Indaptus Therapeutics, Inc.: Filed Certificate of Amendment to effect a 1-for-28 reverse stock split of common stock (effective 2025-06-26).

“on June 26, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split, which became effective as of 5:00 p.m. Eastern Time on June 26, 2025.”

Indaptus Therapeutics, Inc. incurred convertible notes of aggregate principal amount of $2.3 million with certain accredited investors at 6% per year maturing July 28, 2026.

“the offering in a private placement of convertible promissory notes in the aggregate principal amount of $2.3 million (the "Notes") and warrants (the "Warrants") to purchase shares of common stock, par value $0.01 per share ("Common Stock"). The closing of private placement occurred on June 12, 2025”

Indaptus Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 31, 2025, Indaptus Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by the Nasdaq Listing Qualifications (“Nasdaq”) that it is not in compliance with the minimum bid price requirements”

Indaptus Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

“On May 8, 2024, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.”